NTLA Q1 2024 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+129.5% YoY

Gross Profit

$26M91.3% margin

Operating Income

-$114M-394.0% margin

Net Income

-$107M-371.3% margin

EPS (Diluted)

$-1.12

QoQ Revenue Growth

+1609.4%

Cash Flow

Operating Cash Flow

-$121M

Free Cash Flow

-$123M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$223M

Stockholders' Equity

$1.0B

Cash & Equivalents

$172M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$13M	+129.5%
Gross Profit	$26M	-$85M	+131.3%
Operating Income	-$114M	-$112M	-1.8%
Net Income	-$107M	-$103M	-4.2%